Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

The nervous system governs both ontogeny and oncology. Regulating organogenesis
during development, maintaining homeostasis, and promoting plasticity throughout life, the …

Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …

Metabolism of cancer cells is geared toward biomass production and proliferation. Since the
metabolic resources within the local tissue are finite, this can lead to nutrient depletion and …

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Cancer cells rewire their metabolism to survive during cancer progression. In this context,
tumour metabolic heterogeneity arises and develops in response to diverse environmental …

Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …

Targeting tumor cell metabolism is an attractive form of therapy, as it may enhance treatment
response in therapy resistant cancers as well as mitigate treatment-related toxicities by …

Oncogenic mutations in KRAS drive common metabolic programmes that facilitate tumour
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …